
The CEO of Nvidia Admits What Everybody Is Afraid of About AI
The answer, according to Nvidia's CEO Jensen Huang, is that this is not just about stock prices. It's about a fundamental rewiring of our world.
So why is this one company so important? In the simplest terms, Nvidia makes the 'brains' for artificial intelligence. Their advanced chips, known as GPUs, are the engines that power everything from ChatGPT to the complex AI models being built by Google and Microsoft. In the global gold rush for AI, Nvidia is selling all the picks and shovels, and it has made them the most powerful company on the planet.
In a wide ranging interview with CNN's Fareed Zakaria, Huang, the company's leather jacket clad founder, explained what this new era of AI, powered by his chips, will mean for ordinary people.
Huang didn't sugarcoat it. 'Everybody's jobs will be affected, 'Everybody's jobs will be affected. Some jobs will be lost,' he said. Some will disappear. Others will be reborn. The hope, he said, is that AI will boost productivity so dramatically that society becomes richer overall, even if the disruption is painful along the way.
He admitted the stakes are high. A recent World Economic Forum survey found that 41% of employers plan to reduce their workforce by 2030 because of AI. And inside Nvidia itself, Huang said, using AI isn't just encouraged. It's mandatory. One of Huang's boldest claims is that AI's future depends on America learning to build things again. He offered surprising support for the Trump administration's push to re-industrialize the country, calling it not just a smart political move but an economic necessity.
'That passion, the skill, the craft of making things; the ability to make things is valuable for economic growth. It's valuable for a stable society with people who can create a wonderful life and a wonderful career without having to get a PhD in physics,' he said. Huang believes that onshoring manufacturing will strengthen national security, reduce reliance on foreign chipmakers like Taiwan's TSMC, and open high-paying jobs to workers without advanced degrees.
This stance aligns with Trump's tariffs and 'Made in America' push, a rare moment of agreement between Big Tech and MAGA world.
In perhaps his most optimistic prediction, Huang described AI's power to revolutionize medicine. He believes AI tools will speed up drug discovery, crack the code of human biology, and even help researchers cure all disease.
'Over time, we're going to have virtual assistant researchers and scientists to help us essentially cure all disease,' Huang said.
AI models are already being trained on the 'language' of proteins, chemicals, and genetics. Huang says we'll soon see powerful AI partners in labs across the world.
You may not see them yet, but Huang says the technology for physical, intelligent robots already works, and that we'll see them in the next three to five years. He calls them 'VLA models,' short for vision-language-action. These robots will be able to see, understand instructions, and take action in the real world.
Huang didn't dodge the darker side of the AI boom. When asked about controversies like Elon Musk's chatbot Grok spreading antisemitic content, he admitted 'some harm will be done.'
But he urged people to be patient as safety tools improve. He said most AI models already use other AIs to fact-check outputs, and the technology is getting better every day.
His bottom line: AI will be overwhelmingly positive, even if it gets messy along the way.
Jensen Huang talks about AI curing diseases and reshaping work. But here's what's left unsaid: every transformation he describes flows through Nvidia. They make the chips. They set the pace. And now, at $4 trillion, they have the leverage to steer the AI era in their favor. We've seen this playbook before. Tech giants make utopian promises, capture the infrastructure, and then decide who gets access, and at what cost. From Amazon warehouses to Facebook news feeds, the pattern is always the same: consolidation, disruption, control.
The AI hype machine keeps selling inevitability. But behind the scenes, this is a story about raw power. Nvidia is becoming a gatekeeper for what's possible in science, labor, and security. And most of us didn't get a vote.
Huang says harm will happen. But history tells us that when companies promise to fix the world with tech, the harm tends to land on the same people every time.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
What You Need to Know Ahead of W.W. Grainger's Earnings Release
W.W. Grainger, Inc. (GWW), headquartered in Lake Forest, Illinois, distributes maintenance, repair, and operating products and services. Valued at $50.9 billion by market cap, the company's products include motors, HVAC equipment, lighting, hand and power tools, pumps, packaging, material handling, adhesives, safety, janitorial, electrical, and metalworking equipment. The MRO giant is expected to announce its fiscal second-quarter earnings for 2025 before the market opens on Friday, Aug. 1. Ahead of the event, analysts expect GWW to report a profit of $10 per share on a diluted basis, up 2.5% from $9.76 per share in the year-ago quarter. The company surpassed the consensus estimates in two of the last four quarters while missing the forecast on two other occasions. Palantir Just Launched Warp Speed for Warships. Does That Make PLTR Stock a Buy? This Analyst Just Doubled His Price Target on AMD Stock How High Can Nvidia Stock Go as Jensen Huang Heads to China? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For the full year, analysts expect GWW to report EPS of $40.47, up 3.9% from $38.96 in fiscal 2024. Its EPS is expected to rise 11.2% year-over-year to $45.01 in fiscal 2026. GWW stock has outperformed the S&P 500 Index's ($SPX) 11.6% gains over the past 52 weeks, with shares up 15.2% during this period. However, it underperformed the Industrial Select Sector SPDR Fund's (XLI) 21.6% rise over the same time frame. GWW's strong performance can be attributed to two significant factors: a growing shortage of skilled labor, which is prompting businesses to outsource non-core tasks, and the continuous expansion of its product offerings to attract more business from existing customers. These factors are expected to create ample opportunities for the company in the future. On May 1, GWW shares closed up more than 2% after reporting its Q1 results. Its EPS of $9.86 surpassed Wall Street expectations of $9.46. The company's revenue was $4.31 billion, missing Wall Street forecasts of $4.32 billion. GWW expects full-year EPS to be $39 to $41.50, and expects revenue in the range of $17.6 billion to $18.1 billion. Analysts' consensus opinion on GWW stock is cautious, with a 'Hold' rating overall. Out of 16 analysts covering the stock, three advise a 'Strong Buy' rating, 11 give a 'Hold,' one recommends a 'Moderate Sell,' and one advocates a 'Strong Sell.' GWW's average analyst price target is $1,109.55, indicating a potential upside of 4.9% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Here's What to Expect From IDEXX Laboratories' Next Earnings Report
Westbrook, Maine-based IDEXX Laboratories, Inc. (IDXX) develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries. Valued at a market cap of $42.7 billion, the company also offers a range of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. It is scheduled to announce its fiscal Q2 earnings for 2025 before the market opens on Monday, Aug. 4. Before this event, analysts project this pet healthcare company to report a profit of $3.29 per share, up 34.8% from $2.44 per share in the year-ago quarter. The company has surpassed Wall Street's bottom-line estimates in three of the last four quarters, while missing on another occasion. Its earnings of $2.96 per share in the previous quarter topped the consensus estimates by 1.4%. Palantir Just Launched Warp Speed for Warships. Does That Make PLTR Stock a Buy? This Analyst Just Doubled His Price Target on AMD Stock How High Can Nvidia Stock Go as Jensen Huang Heads to China? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For the full year, analysts expect IDXX to report EPS of $12.18, up 14.2% from $10.67 in fiscal 2024. Its EPS is expected to further grow 12.5% year-over-year to $13.70 in fiscal 2026. IDXX has lagged behind the S&P 500 Index's ($SPX) 11.6% return over the past 52 weeks, with its shares up 7.9% during this period. However, it has outpaced the Health Care Select Sector SPDR Fund's (XLV) 8.9% downtick over the same time frame. On May 1, shares of IDXX rose 9% after its Q1 earnings release, despite missing the revenue estimates. The company's revenue improved 3.6% year-over-year to $998.4 million, but fell short of consensus expectations. However, on the upside, both its gross and operating profit margins expanded from the year-ago quarter, leading to a 5.3% increase in its EPS to $2.96, which topped the analyst estimates by 1.4%. IDEXX also raised its fiscal 2025 guidance, now projecting revenue between $4.1 billion and $4.2 billion, and EPS in the range of $11.93 to $12.43. This might have further bolstered investor confidence. Wall Street analysts are moderately optimistic about IDXX's stock, with a "Moderate Buy" rating overall. Among 11 analysts covering the stock, six recommend "Strong Buy," one indicates a "Moderate Buy," and four advise "Hold.' The mean price target for IDXX is $549.50, indicating a 3.4% potential upside from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
17 minutes ago
- Yahoo
Earnings Preview: What to Expect From Revvity's Report
Valued at a market cap of $11.6 billion, Revvity, Inc. (RVTY) provides health sciences solutions, technologies, and services. The Waltham, Massachusetts-based company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. It is expected to announce its fiscal Q2 earnings for 2025 before the market opens on Monday, Jul. 28. Ahead of this event, analysts expect this healthcare company to report a profit of $1.14 per share, down 6.6% from $1.22 per share in the year-ago quarter. The company has topped Wall Street's earnings estimates in each of the last four quarters. In Q1, Revvity's EPS of $1.01 outpaced the forecasted figure by 5.2%. Palantir Just Launched Warp Speed for Warships. Does That Make PLTR Stock a Buy? This Analyst Just Doubled His Price Target on AMD Stock How High Can Nvidia Stock Go as Jensen Huang Heads to China? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! For fiscal 2025, analysts expect RVTY to report a profit of $4.82 per share, down 1.6% from $4.90 per share in fiscal 2024. Nonetheless, its EPS is expected to rebound in fiscal 2026, growing by 14.3% year-over-year to $5.51. Shares of RVTY have declined 10.1% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 11.6% uptick and the Health Care Select Sector SPDR Fund's (XLV) 8.9% loss over the same time frame. On Apr. 28, shares of Revvity closed up marginally after its Q1 earnings release. Due to growth in revenue across both of its reportable segments, the company's overall revenue improved 2.3% year-over-year to $664.8 million. Moreover, its adjusted EPS from continuing operations advanced 3.1% from the year-ago quarter to $1.01 and topped the consensus expectations by 5.2%. Lower adjusted operating income from the diagnostics segment was more than offset by a robust rise in the life sciences segment's profits. Looking ahead, Revvity raised its fiscal 2025 revenue guidance to a range of $2.8 billion to $2.9 billion and reaffirmed its adjusted EPS outlook of $4.90 to $5, which may have further bolstered investor confidence. Wall Street analysts are moderately optimistic about Revvity's stock, with a "Moderate Buy" rating overall. Among 17 analysts covering the stock, 10 recommend "Strong Buy," one indicates a "Moderate Buy," and six advise "Hold.' The mean price target for RVTY is $118.69, indicating a 20.5% potential upside from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio